N4 Pharma plc has appointed a new CEO and changed its name to Thalia Therapeutics plc.

The BioTech firm is developing Nuvec, a proprietary gene delivery system to enable advanced therapies for cancer and other diseases.

It is now also expanding its pipeline to transition to a therapeutic biotechnology company focused on the development of innovative RNA-based therapeutics.

The company has submitted a preliminary patent filing for a novel dual-acting siRNA targeting the reduction of cardiovascular risk.

To implement this accelerated strategy, the company has appointed Dr David H Solomon as CEO to succeed retiring founder Nigel Theobald.